Company record
Direct Rx
0 FDA warning letters since 2023 and 2 recalls in the last 12 months.
Get an email the day FDA posts anything new about Direct Rx.
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| Nov 4 | Class II | Direct Rx Drug |
Lidocaine Ointment USP, 5.0 % 50g JAR, Rx only, Packaged and Distributed by: Direct Rx Dawsonville, GA 30534, NDC 72189-0211-50 Subpotent Drug |
| Jul 1 | Class II | Direct Rx Drug |
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx. CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit |